Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.

Authors:
Acosta MF; Abrahamson MD; Encinas-Basurto D; Fineman JR; Black SM and 1 more

Journal:
AAPS J

Publication Year: 2020

DOI:
10.1208/s12248-020-00531-3

PMCID:
PMC7669792

PMID:
33200330

View on PubMed View on PMC View Publisher
Journal Information

Full Title: AAPS J

Abbreviation: AAPS J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
Gorovits B; Azadeh M; Buchlis G and 12 more (2023) - Transparency Score: 3/6
Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles.
Kim H; Kirtane AR; Kim NY and 6 more (2023) - Transparency Score: 3/6
Lessons from CDER's Quality Management Maturity Pilot Programs.
Maguire J; Fisher A; Harouaka D and 9 more (2023) - Transparency Score: 2/6
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepat…
Purohit V; Huh Y; Wojciechowski J and 5 more (2023) - Transparency Score: 4/6
Benchmarking the Quality Practices of Global Pharmaceutical Manufacturing to Advance Supply Chain R…
Fellows M; Friedli T; Li Y and 8 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"Funding This work was supported by R01HL137282 (HMM, SMB, and JRF), R01HL60190 (SMB), R21AG054766 (HMM), R21AI135935 (HMM and SMB), and P01HL103453 (HMM)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025